Co­herus pulls first in­ter­change­able biosim­i­lar win for Lu­cen­tis copy­cat

Move over, Lu­cen­tis. The FDA has ap­proved the first in­ter­change­able biosim­i­lar to Roche’s block­buster an­ti-VEGF drug.

Co­herus’ Cimer­li is ex­pect­ed to hit the mar­ket in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER